# Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

> **NCT06273943** · PHASE3 · NOT_YET_RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 322 (estimated)

## Conditions studied

- Prevention

## Interventions

- **DRUG:** Cabotegravir Tablets, for oral use.
- **DRUG:** Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
- **DRUG:** Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
- **PROCEDURE:** Rectal Biopsies

## Key facts

- **NCT ID:** NCT06273943
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06273943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06273943, "Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06273943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*